{"id":625681,"date":"2022-11-15T18:52:01","date_gmt":"2022-11-15T18:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=625681"},"modified":"2022-11-15T18:52:01","modified_gmt":"2022-11-15T18:52:01","slug":"acromegaly-market-to-witness-upsurge-in-growth-during-the-forecast-period-202232-examine-delveinsight-key-companies-amryt-chiasma-recordati-novartis-crinetics-pharmaceuticals-camurus-ion","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acromegaly-market-to-witness-upsurge-in-growth-during-the-forecast-period-202232-examine-delveinsight-key-companies-amryt-chiasma-recordati-novartis-crinetics-pharmaceuticals-camurus-ion_625681.html","title":{"rendered":"Acromegaly Market to Witness Upsurge in Growth During the Forecast Period (2022-32), Examine DelveInsight | Key Companies &#8211; Amryt, Chiasma, Recordati, Novartis, Crinetics Pharmaceuticals, Camurus, Ion"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1668503275.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Acromegaly Market to Witness Upsurge in Growth During the Forecast Period (2022-32), Examine DelveInsight | Key Companies - Amryt, Chiasma, Recordati, Novartis, Crinetics Pharmaceuticals, Camurus, Ion\" src=\"https:\/\/www.abnewswire.com\/uploads\/1668503275.png\" alt=\"Acromegaly Market to Witness Upsurge in Growth During the Forecast Period (2022-32), Examine DelveInsight | Key Companies - Amryt, Chiasma, Recordati, Novartis, Crinetics Pharmaceuticals, Camurus, Ion\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Acromegaly Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong><em>Acromegaly is a rare, slowly progressive, acquired disorder that affects adults. The pituitary gland produces too much growth hormone (GH). The pituitary gland is a small gland located near the base of the skull that stores several hormones and releases them into the bloodstream as needed by the body. The acromegaly market dynamics is expected to increase by the major drivers such as rising prevalent population, technological advancements, and upcoming therapies in the 7MM during the forecast period [2019<\/em><\/strong>&ndash;<strong><em>2032).<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s&nbsp;<strong>Acromegaly Market Insights<\/strong>&nbsp;report includes a comprehensive understanding of current treatment practices,&nbsp;acromegaly&nbsp;emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Acromegaly Market Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>In the year 2021, the total diagnosed Acromegaly prevalent cases were 57,824 in the 7MM which are expected to grow during the study period, i.e., 2019&ndash;2032.<\/li>\n<li>Leading acromegaly companies such as&nbsp;<strong>Amryt, Chiasma, Recordati, Novartis Pharmaceuticals, Sun Pharma, Crinetics Pharmaceuticals, Camurus, Ionis Pharmaceuticals,&nbsp;<\/strong>and others are&nbsp;developing novel acromegaly drugs which can be available in the acromegaly market in the upcoming years.<\/li>\n<li>As per DelveInsight analysis, the acromegaly market is anticipated to witness growth at a considerable CAGR.<\/li>\n<li>The acromegaly therapies in the pipeline include&nbsp;<strong>Paltusotine, CAM2029, Cimdelirsen,&nbsp;<\/strong>and others.<\/li>\n<li>The total acromegaly market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major acromegaly markets.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/b0ddd5adedc0cc30f67bda97e8eb447b.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Discover more about therapies set to grab major acromegaly market share @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acromegaly-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Acromegaly Market Landscape<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acromegaly Epidemiology Segmentation<\/strong><\/p>\n<p style=\"text-align: justify;\">The&nbsp;acromegaly market report&nbsp;proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Prevalent Population of Acromegaly<\/li>\n<li>Age-Specific Prevalent Cases of Acromegaly<\/li>\n<li>Gender-Specific Cases of Acromegaly<\/li>\n<li>Diagnosed and treatable Population of Acromegaly<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Download the report to understand which factors are driving acromegaly epidemiology trends @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acromegaly-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Acromegaly Epidemiological Insights<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acromegaly Treatment Market&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">Treatment goals in acromegaly include symptom relief, tumor control with the maintenance of pituitary function, biochemical normalization of GH\/IGF-1, and reversal of the excess morbidity and mortality associated with the disorder. Current modalities of treatment available include surgery, medical therapy, and radiotherapy. Treatment is complex, and more than one modality is frequently required to achieve treatment goals. The primary treatment for acromegaly is transsphenoidal surgery followed by medicinal treatment. Patients who are not eligible for surgery or non-respondent to the surgery are treated with Somatostatin analogs (octreotide, lanreotide, and pasireotide), dopamine agonists (e.g., cabergoline, bromocriptine), or growth hormone receptor antagonists (pegvisomant), either as monotherapy or in combination.<\/p>\n<p style=\"text-align: justify;\">Surgery is the treatment of choice for all microadenomas as well as macroadenomas, causing a mass effect. Debulking of macroadenomas without mass effect can also be done and has been described as a modality to allow for better response to medical treatment even if a surgical cure is not likely. The best predictors of surgical cure include smaller tumor size, lower levels of GH\/IGF-1, and absence of invasion of surrounding structures such as the cavernous sinus. All of these drugs are synthetic somatostatin and bind to somatostatin receptors. And there are three types of surgical techniques like&nbsp;<strong>Endoscopic Transsphenoidal Surgery, Transsphenoidal Microscopic Surgery&nbsp;<\/strong>and&nbsp;<strong>Craniotomy<\/strong>.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>To know more about acromegaly treatment, visit @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acromegaly-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Acromegaly Treatment Guidelines<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acromegaly Pipeline Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Paltusotine: Crinetics Pharmaceuticals<\/li>\n<li>CAM2029: Camurus<\/li>\n<li>Cimdelirsen: Ionis Pharmaceuticals<\/li>\n<li>And many others.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Learn more about the acromegaly drugs in clinical trials @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acromegaly-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Drugs for&nbsp;Acromegaly Treatment<\/a>&nbsp;<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the&nbsp;Acromegaly&nbsp;Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period:<\/strong>&nbsp;2019&ndash;2032<\/li>\n<li><strong>Coverage:<\/strong>&nbsp;7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key&nbsp;Acromegaly&nbsp;Companies:&nbsp;<\/strong>Crinetics Pharmaceuticals,&nbsp;Camurus, Ionis Pharmaceuticals&nbsp;and others<\/li>\n<li><strong>Key<\/strong>&nbsp;<strong>Acromegaly&nbsp;Therapies<\/strong>:&nbsp;Paltusotine, CAM2029, Cimdelirsen and others<\/li>\n<li><strong>Therapeutic Assessment:&nbsp;<\/strong>Acromegaly&nbsp;current marketed and emerging therapies<\/li>\n<li><strong>Acromegaly&nbsp;Market Dynamics:<\/strong>&nbsp;&nbsp;Acromegaly&nbsp;market drivers and barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong>&nbsp;SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Acromegaly Market Access and Reimbursement<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Discover more about&nbsp;acromegaly drugs&nbsp;in development @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acromegaly-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Acromegaly Clinical Trials<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<table style=\"width: 460px;\" border=\"1\" cellspacing=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>\n<p>1.<\/p>\n<\/td>\n<td>\n<p>Acromegaly Market&nbsp;Key Insights<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>2.<\/p>\n<\/td>\n<td>\n<p>Acromegaly Market&nbsp;Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>3.<\/p>\n<\/td>\n<td>\n<p>Acromegaly&nbsp;Market Overview at a Glance<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>4.<\/p>\n<\/td>\n<td>\n<p>Acromegaly Market&nbsp;Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>5.<\/p>\n<\/td>\n<td>\n<p>Disease Background and Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>6.<\/p>\n<\/td>\n<td>\n<p>Acromegaly&nbsp;Treatment and Management<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>7.<\/p>\n<\/td>\n<td>\n<p>Acromegaly&nbsp;Epidemiology and Patient Population<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>8.<\/p>\n<\/td>\n<td>\n<p>Patient Journey<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>9.<\/p>\n<\/td>\n<td>\n<p>Acromegaly&nbsp;Emerging Drugs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>10.<\/p>\n<\/td>\n<td>\n<p>7 Major&nbsp;Acromegaly&nbsp;Market Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>11.<\/p>\n<\/td>\n<td>\n<p>Acromegaly&nbsp;Market Outlook<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>12.<\/p>\n<\/td>\n<td>\n<p>Potential of Current and Emerging Therapies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>13.<\/p>\n<\/td>\n<td>\n<p>KOL Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>14.<\/p>\n<\/td>\n<td>\n<p>Acromegaly&nbsp;Market Drivers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>15.<\/p>\n<\/td>\n<td>\n<p>Acromegaly&nbsp;Market Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>16.<\/p>\n<\/td>\n<td>\n<p>Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>17.<\/p>\n<\/td>\n<td>\n<p>SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>18.<\/p>\n<\/td>\n<td>\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>19.<\/p>\n<\/td>\n<td>\n<p>DelveInsight Capabilities<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>20.<\/p>\n<\/td>\n<td>\n<p>Disclaimer<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>21.<\/p>\n<\/td>\n<td>\n<p>About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.&nbsp; Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform&nbsp;PharmDelve<strong>.<\/strong> <\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=acromegaly-market-to-witness-upsurge-in-growth-during-the-forecast-period-202232-examine-delveinsight-key-companies-amryt-chiasma-recordati-novartis-crinetics-pharmaceuticals-camurus-ion\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=acromegaly-market-to-witness-upsurge-in-growth-during-the-forecast-period-202232-examine-delveinsight-key-companies-amryt-chiasma-recordati-novartis-crinetics-pharmaceuticals-camurus-ion\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Acromegaly Market Acromegaly is a rare, slowly progressive, acquired disorder that affects adults. The pituitary gland produces too much growth hormone (GH). The pituitary gland is a small gland located near the base of the skull that stores several hormones &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/acromegaly-market-to-witness-upsurge-in-growth-during-the-forecast-period-202232-examine-delveinsight-key-companies-amryt-chiasma-recordati-novartis-crinetics-pharmaceuticals-camurus-ion_625681.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,423,404],"tags":[],"class_list":["post-625681","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Professional-Services","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/625681","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=625681"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/625681\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=625681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=625681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=625681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}